Business
Expansion of FractalDx core investigator group
Expansion of FractalDx core investigator group.
About this update from Renalytix Plc
[{"type":"text","content":"\n \nRNS Number : 6141Z Renalytix AI PLC 21 May 2019 \n\nRenalytix AI plc\n(\"RenalytixAI\" or the \"Company\")\n \nRenalytixAI Expands Core Investigator Group\nfor Kidney Transplant Advanced Diagnostic Programme\n \nInvestigators now include transplant experts from University of Oxford, Yale School of Medicine, Emory University School of Medicine, Icahn School of Medicine at Mount Sinai, University of Manitoba, Westmead Hospital Sydney, University of Alabama at Birmingham, and Cleveland Clinic\n \nRenalytix AI plc (AIM: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announces the expansion of the core investigator group supporting clinical and regulatory pathways for FractalDx, a portfolio of advanced diagnostic and prognostic solutions in kidney transplant. \n \nAs previously announced, RenalytixAI formed the FractalDx investigator group as part of its commercial programme for advanced diagnostic tests expected to make significant improvements in the identification and monitoring for kidney transplant rejection, and to aid in accurate dosing of immune-suppression therapy.\n \nKathryn Wood, DPhil, Professor of Immunology Emerita in the Nuffield Department of Surgical Sciences at the University of Oxford, said: \"Predicting transplant rejection before damage to the transplanted kidney occurs remains a major unmet need. Accurately determining rejection risk for each transplant recipient allows individualised treatment to be initiated before the transplanted kidney is attacked and damaged by the immune system leading to improved patient care and successful outcomes.\"\n \nThe number of kidney transplants steadily rises each year in the United States and worldwide1 with nearly 20 percent of transplants failing within three years2. This highlights the critical need for solutions that will address patient impact and the growing cost of medical treatment associated with kidney transplant complications.\n \nDr. Barbara Murphy, Dean for Clinical Integration and Population Health, Professor and System Chair Medicine and Nephrology, at the Icahn School of Medicine at Mount Sinai, and Chair of the Scientific Advisory Board of RenalytixAI, said: \"As the need for kidney transplantation continues to increase due to the rapid growth of the chronic ki...